Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
-
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Anticorps spécifique des myosites
AAV humoral immunity
Muscle
Myositis and muscle disease
Abnormal movement
IMNM
Dermatomyositis
Antiphospholipid syndrome
Antisynthétase
Antisynthetase
Inclusion body myositis
Autoantibodies
Middle Aged
Immune checkpoint inhibitors
AAV vectors
Interferon
Biomarqueurs
Inborn errors of metabolism
AAV antibody
Gene therapy
Myopathy
Amyotrophy
Inflammation
Female
Adverse drug reactions
Anti‐mitochondrial antibodies
Data integration
Lysosomal storage diseases
Machine learning
Cytokines
Multidisciplinarity
Anti-interleukin-6
Auto‐antibodies
Mass cytometry
Interstitial lung disease
Adeno-associated virus vector
DM
Idiopathic inflammatory myopathies
Anti-IgE IgG
AAV
Prognosis
Antibody responses
Adeno-associated virus
Acute Kidney Injury/epidemiology/etiology
Biopsy
Assisted communication devices
Dependovirus/genetics/immunology
Case reports
Myocarditis
Aldostérone
Adult
Polymyositis
Humans
Analyses multidimensionnelles
AAV vector
Aged
Cancer
Bioelectrical impedance analysis
Cardio-oncology
Anti-agalsidase antibodies
Autoimmunity
Immunotherapy
Adolescence
Agalsidase
Pharmacology
IBM
Anémie hémolytique
B cell homeostasis
Systems biology
Antibodies
Biomarker
Adjudication
Auto-antibodies
Animals
Acid-alpha-glucosidase
Auto-immunité
Anti-drug antibodies
Fabry disease
Outcome measures
Deep immune profiling
Arthritis
Male
Myositis
B-lymphocyte
Inflammatory myopathy
Biomarkers
Antisynthetase syndrome
Anti-MDA5 autoantibodies
Amyotrophic lateral sclerosis
Autoantibody
Anti-Mi2
Anti-synthetase syndrome
Autoimmune diseases
Adeno-associated vector
COVID-19
Skeletal muscle
Active
Sphingosine-1-phosphate
Aldosterone
Anticorps anti-agalsidase